Navigation Links
New Drug for Rheumatoid Arthritis Looks Promising.

Patients with rheumatoid arthritis hopes have been raised with Roche announcing that its new drug showed positive results and was safe without any side effects according to its key study. Drug maker Roche Holding AG will file the drug Actemra for regulatory approval in Europe and the U.S. later this year.

Actemra was developed by Japanese pharmaceutical company Chugai Pharmaceutical Co. (4519.TO), which is controlled by Roche. Roche owns the rights to market Actemra outside Japan.

Two other drugs rituximab (Rituxan), abatacept (Orencia) are already there to reduce signs and symptoms of RA, improve physical function and health status, and slow joint damage progression.

Sufferers of rheumatoid arthritis, or RA, begin to experience progressive joint damage early in the disease. The disease differs from what is popularly known as arthritis, typically associated with age-related joint pain; RA is a far more serious inflammatory disease that leads to destruction of cartilage and bone, and can lead to disability.

The new treatment option Actemra in combination with traditional drugs achieved a significant improvement in disease signs and symptoms after 24 weeks, compared to those treated with the traditional drugs alone.

The heterogeneity of the disease is one of the reasons why no single therapy is effective for all patients or for one patient at all times. Disease-modifying anti-rheumatic drugs such as the anti-tumor necrosis factor (TNF) agents etanercept (Enbrel), infliximab (Remicade), and adalimumab (Humira), in combination with methotrexate, have significant anti-inflammatory and joint-protecting activity.

Abatacept, rituximab, and tocilizumab all achieved better clinical results in combination with methotrexate than when used as monotherapy.

Currently available drugs that target a protein called tumour necrosis factor, or TNF, have helped revolutionise treatment for rheum atoid arthritis, but up to 40 percent of patients do not get an adequate response. TNF blockers can also have significant side effects, including serious infections, tuberculosis and increased cancer risk.

"If active disease prevails despite anti-TNF treatment, rituximab or abatacept constitute novel alternatives, although abatacept could be administered before use of a TNF inhibitor (such practice is not currently licensed in Europe). The minimum therapeutic aim is low disease activity, but remission should constitute the ultimate goal." said Josef S. Smolen, M.D., of the Medical University of Vienna, and colleagues.


'"/>




Related medicine news :

1. New treatment for Rheumatoid Arthritis
2. New Rheumatoid Arthritis Treatment
3. New Rheumatoid Arthritis Treatment
4. Consumption Of Red Meat Found To Double The Risk of Rheumatoid Arthritis
5. The Link Between Rheumatoid Arthritis And Heart Failure
6. Smoking during pregnancy increases risk of Rheumatoid Arthritis.
7. Good News For Those Of You Suffering From Rheumatoid Arthritis
8. Mineral Oil exposure increases risk of Rheumatoid Arthritis
9. Mineral Oil exposure increases risk of Rheumatoid Arthritis
10. Novel drug holds promise for treatment of Rheumatoid Arthritis
11. Study Offers Insights Into Treatment Of Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/10/2016)... ... 2016 , ... LaserShip, a regional parcel carrier that services the eastern U.S., ... last Friday in order to aid in the Flint water crisis. In 2014, LaserShip ... located in Clio, only 15 miles away from Flint. , “We have deep roots ...
(Date:2/10/2016)... ... February 10, 2016 , ... As part of its ongoing ... February 2016. Each webinar features a dynamic expert and thoughtful presentation to give ... patients and facilities. Both events are free to attend, but registration is ...
(Date:2/10/2016)... ... 10, 2016 , ... The Wickman Agency in Garland, TX ... local community. Pledging to select a new beneficiary every 60 days, the agency ... goal is to bring community awareness to important local causes by forming campaigns ...
(Date:2/10/2016)... ... ... Dr. Jessica Barron, of Barron Family Dental in Thornton, Colorado , is ... the North Metro Denver area. The new dental practice focuses on comfort where patients ... the most relaxing environment. , While some dental visits can create anxiety for patients, ...
(Date:2/10/2016)... ... ... Gout is like no other joint pain. It strikes suddenly, like flicking on ... redness. It is triggered by the crystallization of uric acid within the joints. It ... to the February 2016 issue of Harvard Men's Health Watch. , The large joint ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ), ... quarter and full year ended December 31, 2015. ... a transformational year for Vanda with the continued growth ... approval of HETLIOZ for Non-24," said Mihael H. Polymeropoulos, ... to our U.S. product portfolio builds on this success ...
(Date:2/10/2016)... -- A new report from business intelligence provider GBI Research - ... disease market will more than double from just under $5 billion in 2014 ... (CAGR) of 11%. Canada , France ... Spain , the UK, and Japan , and will ... Canada , France , Germany ...
(Date:2/10/2016)... , Feb. 10, 2016  CVS Health (NYSE: ... living in Santa Clara County, CA ... on the Santa Clara University campus. CVS Pharmacy stores ... protect patients against the disease. Students at Santa Clara ... get vaccinated. In addition, anyone who has had close ...
Breaking Medicine Technology: